Gary Locke and Patrick McHenry Join the American Biosecurity Initiative as Senior Advisors

Strengthening America's Medical Security: A New Initiative

The American Biosecurity Initiative (ABI) has recently appointed two prominent figures, Gary Locke and Patrick McHenry, as Senior Advisors. This strategic move is part of a broader agenda aimed at reinforcing America's ability to discover, develop, and manufacture medicines — a crucial component of national security.

Meet the Advisors

Gary Locke, who served as the U.S. Secretary of Commerce and the U.S. Ambassador to China, brings invaluable experience to the initiative. His tenure in various government roles, coupled with his background as the Governor of Washington, equips him with a comprehensive understanding of economic competitiveness and the intricacies of U.S.-China relations. Locke emphasizes the necessity for America to prioritize its biotechnology sector decisively, stating, "We should be strengthening what America does best -- discovering new medicines, bringing them to patients, and making more of them here at home."

Patrick McHenry, a former Congressman and Chairman of the House Financial Services Committee, also joins the ABI as a Senior Advisor. From 2005 to 2025, McHenry represented North Carolina's 10th District, contributing significantly to financial legislation. He is currently a Distinguished Fellow at Georgetown University's Psaros Center for Financial Markets and Policy. McHenry articulates the importance of protecting America's leadership in drug discovery, asserting that the nation must adopt a long-term strategy to preserve its advantages in biotechnology.

The Challenge Ahead

As the U.S. continues to be heavily reliant on overseas supply chains for essential pharmaceutical components, the ABI's mission becomes even more pressing. The organization aims to bolster U.S. biopharmaceutical capabilities, curtail vulnerabilities in the supply chain, and secure partnerships with trusted allies in biotechnology. This initiative not only seeks to fortify America's medical supply but also to safeguard national security interests.

ABI's Executive Director, Jennifer Crook, stated, "America cannot defend itself or compete economically without the ability to discover, develop, and manufacture the medicines its citizens and armed forces need." With the ongoing global challenges, especially in the medical and scientific domains, the INA stands adamantly committed to addressing these issues proactively.

Collaborative Leadership

The ABI is assembling a diverse coalition of leaders across various sectors—government, finance, healthcare, intelligence, trade, and national security. This collaboration aims to establish a resilient U.S. biotechnology strategy that withstands political changes and fosters innovation. Locke and McHenry's involvement is anticipated to amplify the initiative, given their extensive backgrounds and understanding of the intersection between economic strength and national security.

Locke and McHenry’s joining marks a significant milestone for the ABI as it endeavors to shape a sustainable approach to securing America's health-related advancements and enhancing its global standing in biotechnology.

A Call to Action

As the ABI engages in its mission, it underscores the urgency for a bipartisan consensus around America's biotechnology strategy. The initiative encourages various stakeholders to join in fostering advancements in scientific research, modernizing regulatory pathways, developing robust domestic manufacturing, and ensuring access to world-class scientific talent.

In conclusion, the roles of Gary Locke and Patrick McHenry as Senior Advisors herald a new chapter for the American Biosecurity Initiative. Their contributions will be pivotal in mobilizing the necessary resources and support to address the medical supply challenges facing the nation. To learn more about the initiative and its mission, visit americanbiosecurity.org.